SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study

Key Takeaways Sanofi's ElevAATe study showed that efdoralprin alfa met all primary and key secondary endpoints.Efdoralprin alfa achieved higher functional AAT levels versus weekly plasma-derived therapy.The therapy's Q3W and Q4W dosing regimen may enhance convenience for AATD patients.Sanofi (SNY) announced that the phase II ElevAATe study, which evaluated its pipeline candidate, efdoralprin alfa, for the treatment of alpha-1 antitrypsin deficiency (AATD) emphysema, met all primary and key secondary endpoin ...